Molecular characterization of HIV-1 subtype C gp-120 regions potentially involved in virus adaptive mechanisms

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Cenci, Alessandra ^a   D'Avenio, Giuseppe ^a   Tavoschi, Lara ^a,f   Chiappi, Michele ^a,g   Becattini, Simone ^a,h   Del Pilar Narino, Maria ^a   Picconi, Orietta ^a   Bernasconi, Daniela ^a,i   Fanales Belasio, Emanuele ^a   Vardas, Eftyhia ^b,d   Sukati, Hosea ^c   Presti, Alessandra Lo ^a   Ciccozzi, Massimo ^a,e   Monini, Paolo ^a   Ensoli, Barbara ^a   Grigioni, Mauro ^a   Buttò, Stefano ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c National Center Public Health Laboratory   (Swaziland)

^d LANCET LABORATORIES   (South Africa)

^e University of Biomedical Campus   (Italy)

^f EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^g CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^h INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

ⁱ ABBOTT DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120;

ADAPTATION; ALPHA HELIX; ARTICLE; BINDING AFFINITY; BINDING SITE; CHRONIC DISEASE; CLADISTICS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; GENETIC CONSERVATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MICROBIAL ACTIVITY; MOLECULAR GENETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN CONFORMATION; PROTEIN GLYCOSYLATION; RECEPTOR BINDING; VIRUS CELL INTERACTION; VIRUS CHARACTERIZATION; VIRUS ENTRY; VIRUS STRAIN; GENETICS; GLYCOSYLATION; METABOLISM; PHYLOGENY; PHYSIOLOGY;

ADAPTATION, PHYSIOLOGICAL; GLYCOSYLATION; HIV ENVELOPE PROTEIN GP120; HIV-1; PHYLOGENY;

EID: 84899738851     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095183     Document Type: Article

References (63)

1. Starcich BB, Hahn BH, Shaw GM, McNeely PD, Modrow S, et al. (1986) Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 45: 637-648. (Pubitemid 16063128)
2. Curlin ME, Zioni R, Hawes SE, Liu Y, Deng W, et al. (2010) HIV-1 envelope subregion length variation during disease progression. Plos Pathog 6: e1001228.
3. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586. (Pubitemid 26097216)
4. Coffin JM (1995) HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy. Science 267: 485-489.
5. Pollakis G, Kang S, Kliphuis A, Chalaby MI, Goudsmit J, et al. (2001) N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem 276:13433-13441.
6. Moore, P.L. Ranchobe N, Lambson BE, Gray ES, Cave E, et al. (2009) Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. Plos Pathog 5: e1000598.
7. Goudsmit J, Back NK, Nara PL (1991) Genomic diversity and antigenic variation of HIV-1: links between pathogenesis, epidemiology and vaccine development. FASEB J 5: 2427-2436. (Pubitemid 21905791)
8. Letvin NL, Walker BD (2003) Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med 9: 861-866. (Pubitemid 36889927)
9. Cenci A, Tavoschi L, D' Avenio G, Narino P, Becattini S, et al. (2012) Characterization of variable regions of the gp120 protein from HIV-1 subtype C virus variants obtained from individuals at different disease stages in Sub-Saharan Africa. J AIDS Clin Res S8-006.
10. Rong, R. Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, et al. (2007) Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 81: 1350-1359. (Pubitemid 46167856)
11. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659. (Pubitemid 28289647)
12. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, et al. (1995) Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 69: 5723-5733.
13. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, et al. (2004) Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303: 2019-2022. (Pubitemid 38393277)
14. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312. (Pubitemid 36378357)
15. Sagar M, Wu X, Lee S, Overbaugh J (2006) Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 80: 9586-9598. (Pubitemid 44435633)
16. Liu Y, Curlin ME, Diem K, Zhao H, Ghosh AK, et al. (2008) Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B viruses. Virology 374: 229-233.
17. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H (2008) Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 82: 7932-7941.
18. Coetzer M, Cilliers T, Papathanasopoulos M, Ramjee G, Karim SA, et al. (2007) Hum Longitudinal analysis of HIV type 1 subtype C envelope sequences from South Africa. AIDS Res Hum Retrov 23: 316-321. (Pubitemid 46418346)
19. Gaschen B, Taylor J, Yusim K, Foley B, Gao F at al. (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360 (Pubitemid 34734202)
20. Zhang H, Hoffmann F, He J, He X, Kankasa C, et al. (2005) Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant. Retrovirology 2: 67.
21. Arien KK, Vanham G, Arts EJ (2007) Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol 5: 141-151. (Pubitemid 46151872)
22. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, et al. (2005) Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 102: 18514-18519. (Pubitemid 43011257)
23. Patel MB, Hoffman NG, Swanstrom R (2008) Subtype specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J Virol 82: 903-916.
24. Gnanakaran, S. Lang D, Daniels M, Bhattacharya T, Derdeyn CA, et al. (2007) Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. J Virol 81: 4886-4891. (Pubitemid 46668687)
25. Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, et al. (2010) Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS ONE 5: e10254.
26. Felsovalyi K, Nadas A, Zolla-Pazner S, Cardozo T (2006) Distinct sequence patterns characterize the V3 region of HIV type 1 gp120 from subtypes A and C. AIDS Res Hum Retrov 22: 703-708.
27. Rong R, Gnanakaran S, Decker JM, Bibollet-Ruche F, Taylor J, et al. (2007) Unique mutational patterns in the envelope α2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C Human Immunodeficiency Virus type 1. J Virol 81: 5658-5668. (Pubitemid 46847005)
28. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, et al. (2008) The C3-V4 region is a major target of autologous neutralizing antibodies in Human Immunodeficiency Virus type 1 subtype C infection. J Virol 82: 1860-1869. (Pubitemid 351206934)
29. Choisy M, Woelk CH, Guégan JF, Robertson DL (2004) Comparative study of adaptive molecular evolution in different Human Immunodeficiency Virus groups and subtypes J Virol 78: 1962-1970. (Pubitemid 38176728)
30. Yamaguchi-Kabata Y, Gojobori T (2000) Reevaluation of amino acid variability of the Human Immunodeficiency Virus type 1 gp120 envelope glycoprotein and prediction of new discontinuous epitopes. J Virol 74: 4335-4350. (Pubitemid 30214442)
31. Olshevsky U, Helseth E, Furman C, Li J, Haseltine W, et al. (1990) Identification of individual Human Immunodeficiency Virus type 1 gpl20 amino acids important for CD4 receptor binding. J Virol 64:5701-5707.
32. Rizzuto C, Sodroski J (2000) Fine definition of a conserved CCR5-binding region on the Human Immunodeficiency Virus type 1 glycoprotein gp120. AIDS Res Hum Retrov 16: 741-749. (Pubitemid 30327291)
33. Swaziland Demographic and Health Survey (2006-2007). Central Statistical Office, Ministry of Economic Planning and Development, Swaziland.
34. Bernasconi D, Tavoschi L, Regine V, Raimondo M, Gama D, et al. (2010) Identification of recent HIV infections and of factors associated with virus acquisition among pregnant women in 2004 and 2006 in Swaziland. J Clin Virol 48: 180-183
35. Suligoi B, Buttò S, Galli C, Bernasconi D, Salata RA, et al. (2008) Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity. J Clin Virol 41: 288-292.
36. Hall TA (1999) Bioedit a user-friendly biological sequence alignment, editor and analysis program for Windows 95/98 NT. Nucl Acids Symp Ser 41: 95-98.
37. Posada D, Crandall KA (1998) MODELTEST: testing the model of DNA substitution. Bioinformatics 14: 817-818. (Pubitemid 28552116)
38. Jukes T, Cantor CR (1969) Evolution of protein molecules. In Mammalian protein metabolism. Edited by Munro HN. New York: Academic Press pp. 21-132.
39. Bhatta H, Goldys EM (2009) Quantitative characterization of different strains of Saccharomyces yeast by analysis of fluorescence microscopy images of cell population. J Microbiol Methods 77: 77-84.
40. Yang Z (1997) PAML: a program package for the phylogenetic analysis by maximum likelihood. Comput Appl Biosci 13: 555-556.
41. Yang Z, Nielsen R, Goldman N, Pedersen AM (2000) Codon substitution models for heterogeneous selection pressure at amino acid sites. Genetics 155: 431-444.
42. Anisimova M, Bielawsky JP, Yang Z (2001) Accuracy and power of likelihood ratio test in detecting adaptive evolution. Mol Biol Evol 18: 1585-1592. (Pubitemid 32735106)
43. Yang Z, Wong WS, Nielsen R (2005) Bayes empirical Bayes inference of amino acid sites under positive selection. Mol Biol Evol 22: 1107-1118. (Pubitemid 40471423)
44. Sokal RR, Rohlf FJ. Biometry. W. H. Freeman and Company, New York, N.Y (1981).
45. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, et al. (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025-1028. (Pubitemid 41611916)
46. Auwerx J, François KO, Covens K, Van Laethem K, Balzarini J (2008) Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention. J Virol 382: 10-19.
47. Huang X, Jin W, Hu K, Luo S, Du T, et al. (2012) Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. Virology 423: 97-106.
48. Sharon RL, Kessler N, Levy R, Zolla-Pazner S, Görlach M, et al. (2003) Alternative conformations of HIV-1 V3 loops mimic B hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure 12: 225-236. (Pubitemid 36183646)
49. Tscherning C, Alaeus A, Fredriksson R, Björndal A, Deng H, et al. (1998) Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 241: 181-188. (Pubitemid 28384191)
50. Cilliers T, Nhlapo J, Coetzer M, Orlovic D, Ketas T, et al. (2003) The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol 77: 4449-4456. (Pubitemid 36350986)
51. Lin NH, Smeaton LM, Giguel F, Novitsky V, Moyo S, et al. (2011) Prevalence and clinical associations of CXCR4-using HIV-1 among treatment-naive subtype C-infected women in Botswana. J Acquir Immune Defic Syndr 57: 46-50.
52. Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, et al. (2004) Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and Influenza hemagglutinin. Glycobiology 14: 1229-1246. (Pubitemid 39585357)
53. Ogert RA, Lee MK, Ross W, Buckler-White A, Martin MA, et al. (2001) N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism. J Virol 75: 5998-6006. (Pubitemid 32553130)
54. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, et al. (2007) Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 81: 6187-6196. (Pubitemid 46878025)
55. Sterjovski J, Churchill MJ, Ellett A, Gray LR, Roche MJ, et al. (2007) Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 4: 89.
56. Peut V, Kent JS (2006) Fitness constraints on immune escape from HIV: Implications of envelope as a target for both HIV-specific T cells and antibody. Curr HIV Res 4: 191-197.
57. Dacheaux L, Moreau A, Ataman-Onal Y, Biron F, Verrier B, et al. (2004) Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope. J Virol 78: 12625-12637. (Pubitemid 39458780)
58. Carducci F, Marinozzi MC, Sampaolo M, Berrè S, Bagnarelli P, et al. (2009) Dynamic features of the selection pressure on the Human Immunodeficiency Virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects. Retrovirology 6: 4.
59. Aasa-Chapman MM, Seymour CR, Williams I, McKnight A (2006) Novel envelope determinants for CCR3 use by human immunodeficiency virus. J Virol 80: 10884-10889. (Pubitemid 44628937)
60. Kumar R, Tuen M, Li H, Tse DB, Hioe CE (2011) Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation. Vaccine 29: 9064-9074.
61. Li H, Chien PC Jr, Tuen M, Visciano ML, Cohen S, et al. (2008) Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes. J Immunol 180: 4011-4021.
62. Korber BTM, MacInnes K, Smith RF, Myers G (1994) Mutational trends in V3 loop protein sequences observed in different genetic lineages of Human Immunodeficiency Virus type 1. J Virol 68: 6730-6744. (Pubitemid 24294924)
63. Kumar R, Tuen M, Li H, Tse DB, Hioe CE (2011) Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation. Vaccine 29: 9064-9074.